Patents by Inventor Natalia Morsci

Natalia Morsci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AAV-MEDIATED DELIVERY OF ATP1A3 GENES TO CENTRAL NERVOUS SYSTEM
    Publication number: 20230381340
    Abstract: This invention relates to a transgenic vector for transducing cells of a mammal's CNS and transgenically expressing a protein in the mammal's CNS. The transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter sequence. This invention also relates to a composition comprising a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, in a form compatible with administration into the CNS. The invention also relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene and a method for delivering a transgenic ATP1A3 DNA to the central nervous system of a mammal by administering the recombinant AAV vector into the mammal's CNS.
    Type: Application
    Filed: August 14, 2023
    Publication date: November 30, 2023
    Inventors: Simon Frost, Natalia Morsci, Neil Hackett, Dolan Sondhi
  • AAV-mediated delivery of ATP1A3 genes to central nervous system
    Patent number: 11738093
    Abstract: This invention relates to a transgenic vector for transducing cells of a mammal's CNS and transgenically expressing a protein in the mammal's CNS. The transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter sequence. This invention also relates to a composition comprising a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, in a form compatible with administration into the CNS. The invention also relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene and a method for delivering a transgenic ATP1A3 DNA to the central nervous system of a mammal by administering the recombinant AAV vector into the mammal's CNS.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: August 29, 2023
    Assignees: Hope for Annabel, Cure AHC, Inc., Alternating Hemiplegia of Childhood Foundation
    Inventors: Simon Frost, Natalia Morsci, Neil Hackett, Dolan Sondhi
  • AAV-MEDIATED DELIVERY OF ATP1A3 GENES TO CENTRAL NERVOUS SYSTEM
    Publication number: 20190358346
    Abstract: This invention relates to a transgenic vector for transducing cells of a mammal's CNS and transgenically expressing a protein in the mammal's CNS. The transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter sequence. This invention also relates to a composition comprising a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, in a form compatible with administration into the CNS. The invention also relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene and a method for delivering a transgenic ATP1A3 DNA to the central nervous system of a mammal by administering the recombinant AAV vector into the mammal's CNS.
    Type: Application
    Filed: April 9, 2019
    Publication date: November 28, 2019
    Inventors: Simon Frost, Natalia Morsci, Neil Hackett, Dolan Sondhi